Hatteras Venture Partners is a healthcare venture capital firm investing in biotechnology, medical devices and health technology. It backs companies from formation and seed-stage science through clinical development and commercial growth. The firm helps founders with company building, recruitment, regulatory and clinical planning, business development and follow-on financing.
Founded
2000
Type
Venture capital
Funds3
Hatteras Opportunity Fund II—
Fund for concentrated follow-on investments in selected Hatteras portfolio companies approaching clinical, regulatory and commercial milestones. Its first close was announced September 30, 2026. The $100 million fundraising target is not a disclosed amount raised at that close.
Hatteras Opportunity Fund I—
Follow-on fund for selected later-stage Hatteras portfolio companies. Final close announced alongside Hatteras Venture Partners VII with more than $200 million in combined commitments; the announcement does not disclose this fund’s individual size.
Hatteras Venture Partners VII—
Seed- and early-stage healthcare venture fund. Final close announced alongside Hatteras Opportunity Fund I with more than $200 million in combined commitments; the announcement does not disclose this fund’s individual size.
Arboretum Ventures
Pharaoh Neuro$20M · 2026-02-18
Dolby Family Ventures
Sensorium Therapeutics$— · Unknown date
IAG Capital Partners
Laerdal Million Lives Fund
Qoniq